DiaMedica Therapeutics (DMAC) Accumulated Expenses (2017 - 2026)

DiaMedica Therapeutics (DMAC) has reported Accumulated Expenses for 10 consecutive years, with $3.7 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Accumulated Expenses rose 33.45% year-over-year to $3.7 million; the trailing twelve-month figure through Jun 2026 stood at $3.7 million (up 33.45% YoY), and the FY2025 full-year result was $3.5 million, down 18.45% from the prior year.
• Accumulated Expenses grew to $3.7 million in Q2 2026 per DMAC's latest filing, from $2.3 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $4.3 million in Q4 2024 and bottomed at $637000.0 in Q3 2022.
• Historically, Accumulated Expenses has averaged $2.2 million across 5 years, with a median of $2.0 million in 2024.
• The sharpest annual moves came in 2022 and 2024: Accumulated Expenses fell 26.02% in 2022, then jumped 146.45% in 2024.
• Over 5 years, Accumulated Expenses stood at $1.4 million in 2022, then surged by 30.18% to $1.8 million in 2023, then soared by 144.63% to $4.3 million in 2024, then retreated by 18.45% to $3.5 million in 2025, then advanced by 3.41% to $3.7 million in 2026.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $3.7 million, $2.3 million, and $3.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.